KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Optimistic Bias and Personality Factors in Adherence to Oral Anticancer Treatments in Metastatic Breast Cancer: A Retrospective Analysis of Data From a Randomized Controlled Trial. PMID 41172984 · Cancer Control · 2025 The study is a secondary analysis of an RCT focusing on adherence and psychological factors, not the original trial report. It does not report on a primary or key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials. PMID 41169385 · Front Immunol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Cost-effectiveness of cadonilimab plus chemotherapy vs chemotherapy alone for advanced gastric cancer: evidence to inform drug pricing in the U.S. and China. PMID 41164188 · Front Immunol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules. PMID 41164107 · Front Mol Med · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Expert Opinion Report on the Challenges in the Management of Psoriatic Arthritis in United Arab Emirates: A Focus on Interleukin-17 Inhibitors. PMID 41158207 · Open Access Rheumatol · 2025 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Transcutaneous Auricular Vagus Nerve Stimulation for Prevention of Postoperative Delirium in Older Adults Undergoing Total Knee Arthroplasty: A Multicenter Randomized Controlled Trial Protocol. PMID 41146865 · Clin Interv Aging · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Antibody response to tetanus, diphtheria, poliomyelitis, hepatitis B, and H. influenzae b vaccines in allogeneic hematopoietic stem cell transplant adult recipients: A multicenter trial. PMID 41144397 · PLoS One · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
On-treatment modified Glasgow Prognostic Score (mGPS) in hepatocellular carcinoma treated with atezolizumab and bevacizumab provides prognostic information. PMID 41142780 · Front Immunol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma. PMID 41142252 · Front Pharmacol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of Baofukang suppository on the relative indexes of epithelial mesenchymal transformation of tumor cells and prognosis in patients with cervical cancer. PMID 41139264 · Pak J Pharm Sci · 2025 The record describes a randomized trial in cervical cancer patients with a drug-containing intervention, but the abstract reports only surrogate/biomarker outcomes (EMT markers, cytokines, immune cells) and safety. It does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or Kaplan-Meier/HR analysis. The phase is not explicitly stated.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma. PMID 41122636 · Front Oncol · 2025 The report presents pre-specified secondary endpoints of health-related quality of life (PROs) from a phase 3 randomized trial, but does not include primary or key secondary time-to-event efficacy endpoints such as OS, PFS, or DFS. The analysis is focused on patient-reported outcomes, which are excluded from the cohort criteria.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Metronomic chemotherapy of paclitaxel plus cisplatin in patients with metastatic breast cancer: a target trial emulation study. PMID 41122314 · Ther Adv Med Oncol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Outcomes of endoscopic third ventriculostomy in comparison to ventriculoperitoneal shunt in obstructive hydrocephalus - A randomized controlled trial. PMID 41112363 · Surg Neurol Int · 2025 The study is not oncology-focused (obstructive hydrocephalus) and lacks a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Baseline CD4+/CD8+ TEMRA Levels and Early Response Predict Survival After Umbilical Cord-Derived Mesenchymal Stem Cells Infusion in Acute GVHD Patients: A Randomized Double-Blinded Placebo-Controlled Multicentre Clinical Trial. PMID 41084724 · J Blood Med · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Prevalence of Molecular Markers of Resistance to Antimalarial Drugs Three Years After Perennial Malaria Chemoprevention in Sierra Leone. PMID 41080970 · Gates Open Res · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Metformin and estrogen modulation in LABC with T2DM: A 36-month randomized trial. PMID 41079227 · Open Med (Wars) · 2025 The study is a randomized drug trial in human oncology with time-to-event endpoints and original results. However, it is not eligible because the trial phase is not established as Phase III/IIIb or Phase II/III (a required criterion), and the design is not a standard definitive randomized controlled trial as per the criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Protection From SARS-CoV-2 Infection With an Oral Nosode (BiosimCovex): A Randomized, Double-Blind, Placebo-Controlled, Phase III Study. PMID 41064737 · Glob Adv Integr Med Health · 2025 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of hybrid remote neuropsychological rehabilitation on cognitive complaints in post-therapeutic lower-grade glioma: the FREEDOME randomized study protocol. PMID 41064168 · Front Psychol · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Safety and efficacy of vilaprisan in Japanese women with fibroids: The Phase 3 ASTEROID 8 trial. PMID 41059527 · Womens Health (Lond) · 2025 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H L S B
旧组与严格 v3 交集 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Safety & efficacy of thulium laser endoscopic en bloc resection versus conventional trans urethral resection of bladder tumors, for treatment of non muscle invasive bladder tumors: A prospective randomized trial. PMID 41050386 · Arab J Urol · 2025 Eligibility criteria not met: study lacks a drug-containing intervention (compares surgical techniques) and lacks a time-to-event primary/key secondary efficacy endpoint (recurrence rate is a categorical outcome at 12 months, not a survival/recurring event analyzed with KM/HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of the thumbtack needle on gastrointestinal function recovery after laparoscopic radical gastrectomy for gastric cancer with the concept of enhanced recovery after surgery: a randomized controlled trial. PMID 41050349 · Front Surg · 2025 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Efficacy of Endostar plus concurrent chemoradiotherapy in locally advanced cervical cancer: a multicenter, phase II randomized trial. PMID 41049580 · Ther Adv Med Oncol · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comparing Quality of Life for Billroth II With Braun Versus Uncut Roux-en-Y Reconstruction After Total Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Clinical Trial. PMID 41042207 · Cancer Control · 2025 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA). PMID 41040645 · Wellcome Open Res · 2025 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Bowel Preparation for Colonoscopy: The Patient Point of View. PMID 41021426 · Dig Dis · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized controlled trials. PMID 41018097 · Front Oncol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparison of Postoperative Analgesic Effects of Intravenous versus Perineural Dexamethasone Injection Combined with Ropivacaine in Thoracoscopy-Guided Thoracic Paravertebral Block for Thoracoscopic Radical Lung Cancer Resection: A Prospective Randomized Controlled Trial. PMID 41017807 · Drug Des Devel Ther · 2025 Study is a randomized, prospective, human oncology trial, but it lacks a drug-containing intervention (the intervention is anesthetic technique and analgesic adjuvant) and does not report a time-to-event efficacy endpoint (OS, PFS, etc.) with Kaplan-Meier analysis or hazard ratios.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dual-target immunotherapies in NSCLC: a systematic review and meta-analysis of randomized clinical trials. PMID 41000392 · Front Immunol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Case report: Curative effect and mechanism of surufatinib combined with toripalimab in the treatment of 1 case of lung large-cell neuroendocrine carcinoma. PMID 40989691 · Front Oncol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Assessing the clinical benefit from medical therapies in CNS malignancies: Refining the ESMO Magnitude of Clinical Benefit Scale and the ASCO Value Framework. PMID 40980453 · Neurooncol Adv · 2025 This publication is a methodological study that applies and validates clinical benefit assessment scales (ESMO-MCBS, ASCO, Neuro-MCBS) to a collection of existing neuro-oncology studies. It is not an original result report of a single randomized trial with a drug intervention and a time-to-event efficacy endpoint. The abstract describes the development and testing of a scoring tool, not the presentation of trial-specific efficacy data.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial. PMID 40971945 · PLoS One · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
DEHyART trial: Study protocol for phase 2 randomised controlled study assessing the role of dose escalation using [18F] fluoromisonidazole positron emission tomography/computed tomography in head and neck cancers. PMID 40949474 · Ecancermedicalscience · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effect analysis of percutaneous catheter drainage combined with radiofrequency ablation in the treatment of mixed thyroid nodules. PMID 40937415 · Front Endocrinol (Lausanne) · 2025 The study is a randomized trial on benign thyroid nodules (non-malignant), uses a non-drug intervention (radiofrequency ablation and catheter drainage), and reports outcomes such as tumor size, treatment duration, pain, hoarseness, and recurrence counts without Kaplan-Meier or HR analysis, failing to meet eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cost-Effectiveness of Photodynamic Therapy and 5-Fluorouracil Cream versus Surgical Excision in Treatment of Bowen's Disease: A Trial-Based Economic Evaluation. PMID 40934140 · Dermatology · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors. PMID 40924700 · PLoS One · 2025 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Generic Intravenous Amisulpride (QLG2069) for the Prevention of Postoperative Nausea and Vomiting in Adults: A Phase III, Multicenter, Randomized, Placebo-Controlled Study. PMID 40923005 · Drug Des Devel Ther · 2025 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028. PMID 40918097 · Front Immunol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Strategy-based cognitive rehabilitation for childhood brain tumour: Protocol for an acceptability and feasibility trial of the Fatigue, Learning, and Memory Enrichment (FLaME) intervention. PMID 40917737 · NIHR Open Res · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Feasibility of Intravaginal Artesunate as an Adjuvant HPV & Cervical Precancer Treatment Among Women Living With HIV in Kenya: Study Protocol for a Phase II Clinical Trial. PMID 40907021 · Cancer Control · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Evaluation of a digital health platform for preventing stroke in the Australian community: Study protocol for a randomized controlled trial - Love Your Brain. PMID 40906720 · PLoS One · 2025 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease. PMID 40904419 · Alzheimers Dement (N Y) · 2025 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
[Future directions in the management of warm autoimmune hemolytic anemia]. PMID 40903253 · Rinsho Ketsueki · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Short-course PD-1 blockade in locally advanced nasopharyngeal carcinoma: a phase II randomized trial protocol (Tori-013). PMID 40901464 · Front Immunol · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Study protocol for a randomized controlled clinical trial of a multifaceted cognitive training program using video games in childhood cancer survivors. PMID 40892751 · PLoS One · 2025 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effectiveness of radiofrequency and exercise-based rehabilitation on symptoms associated with pelvic floor dysfunction in breast cancer patients: A study protocol. PMID 40880350 · PLoS One · 2025 The record is a study protocol, not a formal result report. It lacks reported efficacy data. Furthermore, it does not meet core eligibility criteria: the trial phase is not explicitly established as Phase III/IIIb or Phase II/III, the interventions are non-drug only (radiofrequency and pelvic floor muscle training), and the primary endpoints are not time-to-event efficacy measures (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Low Th2 and high PD1+ TFh cells in blood predict remission after CTLA-4Ig treatment for 48 weeks in early rheumatoid arthritis. PMID 40875656 · PLoS One · 2025 The record describes a randomized trial in rheumatoid arthritis, not oncology. While it is a human randomized trial with drug interventions and reports survival analysis for remission, the disease is non-oncologic and the endpoint (time to remission in RA) is not an oncology time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Bibliometric analysis of biologic treatments for chronic rhinosinusitis. PMID 40861204 · Front Med (Lausanne) · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The anti-inflammatory and antioxidant effects of astaxanthin as an adjunctive therapy in community-acquired pneumonia: a randomized controlled trial. PMID 40852606 · Front Pharmacol · 2025 The study is not an oncology trial; it is a randomized controlled trial for community-acquired pneumonia, a non-malignant condition. The primary endpoint is inflammatory markers, not a time-to-event efficacy outcome. The intervention is a supplement (astaxanthin), not a cancer drug. Therefore, it is excluded on multiple grounds.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact on outcomes of ultra hypofractionation or hypofractionation regimens and proton or Xrays therapy in a phase III randomized controlled trial MC1635. PMID 40842574 · Front Oncol · 2025 The record is a Phase III randomized controlled trial in oncology, but it lacks a specified time-to-event efficacy endpoint (e.g., OS, PFS, DFS) and the intervention appears to be radiation therapy (hypofractionation/proton vs. X-ray) without a drug component, making it ineligible.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Correction: Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer-an open-label phase 2 randomized controlled trial. PMID 40823083 · Front Oncol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -